WORLD’S FIRST DIGITAL WHEEZE DETECTION & MEASUREMENT TECHNOLOGY
Respiri leads the way in new technologies to better manage asthma, a chronic disease affecting over 330 million people worldwide and growing.
wheezo diary app now available
wheezo is your asthma personal assistant. It helps you better understand how asthma affects you so you can do all the things you love doing. You can log how your breathing feels, symptoms and triggers and medication usage. You can also set medication reminders to help improve asthma control. When it’s time to visit your doctor, wheezo will provide a simple and accessible picture of your asthma history. wheezo helps you manage your asthma worries. Features:
Self-assessment - Log how your breathing feels, your symptoms and any triggers throughout the day.
Log Medication – Record your preventer and reliever use and set reminders for better asthma control.
View History – See how your asthma is tracking over time and share it with your doctor.
INDIA JOINT VENTURE AGREEMENT
ASX ANNOUNCMENT – 3 May 2019
Respiri limited (ASX: RSH) (“Respiri” or the “Company”) is pleased to announce a joint venture agreement for the company’s entry into India with MedAchievers Private Limited (“MedAchievers”) – an integrated platform for global healthcare. Dr Harsha Vardhan is the Founder and Group Managing Director, and the Joint Venture will be supported by Australian- India business trade expert Mr Michael Koss.
For Respiri to successfully enter India, it is of critical importance to identify the best possible local healthcare leaders with key relationships in Tier 1 and 2 private hospitals (hospital owners, lead pulmonologists etc). From this perspective, the company is delighted with the progress achieved to date in working with MedAchievers, Dr Harsha Vardhan and Mr Michael Koss. Respiri and MedAchievers have a clearly defined market engagement strategy that is targeting first Indian sales in October/November.
Boardroom Media talks with Mario Gattino
Thursday, May 9, 2019
Products
Respiri’s innovative devices and apps use digital wheeze detection and measurement technology, replacing outdated and difficult-to-use instruments for lung function testing such as peak flow meters.
Healthcare
Respiri’s clinically proven patented technology is used in major hospitals in UK, Europe, USA, Japan, Korea and Australia.
Investors
Respiri operates in an industry subset of the globally attractive health and technology sectors and is well positioned as one of the few companies in the world producing the next wave of consumer focused technology for complex disease management.
Technology
Our unique proprietary Acoustic Respiratory Monitoring (ARM™) technology records airway sounds to detect continuous adventitious breath sounds (CABS) and measure the extent of wheezing caused by airway obstruction.
Respiri devices work like a stethoscope, utilizing contact sensors to acquire breath sounds at the windpipe (trachea).
CORPORATE NEWS
Respiri Limited (ASX:RSH) is an Australian owned company with revolutionary smart tools to empower people with asthma and improve outcomes. For over 330 million people worldwide, the simple act of breathing can be a terrifying daily ordeal. Asthma affects quality of life, productivity at work and school and at its worse, still kills. Backed by over twenty years of research by respiratory specialists, and with first-move advantage, Respiri offers an over-the-counter monitoring solution that will help people manage asthma in ways that have never been available before.
Conference call: Shareholder Update Presentation
April 21, 2020
5 ASX Minnows in Healthcare Amid COVID-19 – NVU, ZNO, HCT, GMV, RSH
A genie has been set out of the bottle, in the form of an unprecedented virological threat. Amid the pandemic, does the opportunity for healthcare sector surpass the challenges it is facing? 5 ASX minnows from ASX healthcare space are demonstrating this as they tackle COVID-19.
Source: Kalkine Media
Shareholders back Respiri in heavily oversubscribed share purchase plan
Respiri has topped up its cash reserves with $3.14 million after receiving “significant oversubscriptions” in a recent share purchase plan.
The company launched the share purchase plan last month, with the original offer to raise $1 million by issuing shares at $0.055.
Source: Small Caps
Shareholders back Respiri’s new story with strong support for capital raise
Special Report: eHealth SaaS company Respiri has raised $3.14m in a heavily oversubscribed capital raising, taking its total funds raised to $5.2m
Source: Stockhead
Respiri pushes ahead with regional expansion after signing key distribution deal
Special Report: The deal with telehealth platform Practice Innovators International will give Respiri more exposure to a fast-growing sector.
Source: Stockhead
Respiri strikes telehealth deal with Aussie start-up to improve respiratory care for asthma patients
Respiri will integrate its wheezo eHealth SaaS monitoring platform into the GPNow telehealth system.
Source: Small Caps
Respiri to enter asthma telehealth, wheezo commercialisation looms
Under new management, medtech company Respiri (ASX: RSH) is poised to enter the lucrative SaaS revenue market by leveraging their asthma screening device to partner with Phenix Healthcare, whose patients will be able to monitor their condition using Respiri’s wheezo device.
Source: The Sentiment
Stock Talk: TeleHealth in a COVID-19 world and beyond
Stock Talk is a new Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this first edition, host Dr Nigel Finch examines the coronavirus-induced boom of the telehealth industry.
Source: Stockhead
Respiri experiences requests for wheezo devices to monitor COVID-19 patients in China
Respiri has approved applications from three hospitals in China for wheezos devices to test patients with experiencing respiratory problems caused by coronavirus infection.
Source: Small Caps
Small Caps podcast
Marjan Mikel joins Small Caps to discuss Wheezo, the world’s first digital wheeze detection and measurement technology.
Health-tech company Respiri finds demand amid the chaos; closes $2m share placement
The COVID-19 pandemic is making capital harder to come by for businesses across the board.
But listed health-tech platform Respiri (ASX:RSH) still managed to close the deal, announcing the completion of its $2m share placement yesterday.
Amid the broader market turbulence, Respiri’s offer found demand from sophisticated investors who snapped up a total of 36,363,637 shares priced at 5.5c.
Source: Stockhead
Remote control: 5 medtechs set to benefit from the surge in demand for tele-health solutions
The coronavirus-induced market carnage of the last few weeks has rattled plenty of investor nerves.
But as with any major correction, some industries feel the brunt of the impact while for others, the dramatic shift presents an opportunity.
Source: Stockhead
The Sydney Morning Herald
How asthmatics are unknowingly putting themselves in danger
A majority of people who think they have their asthma under control are wrong and are putting themselves at serious risk of severe and potentially life-threatening flare-ups during this unprecedented bushfire season.
Respiri receives European Smart Healthcare Technology Innovation Award
Respiri is pleased to announce it has earned Frost & Sullivan’s 2019 European Smart Healthcare Technology Award for ‘its strong overall performance and commendable technology leverage’.
Frost & Sullivan Best Practices Awards are independent, research backed accolades that
recognise companies throughout a range of regional and global markets. Its industry analyst team benchmarks market participants and measures their performance through independent primary interviews and secondary industry research in order to evaluate and identify best practices.
Frost & Sullivan analysts independently evaluated the performance of Respiri and other companies in healthcare technology on two key factors – Technology Attributes and Future Business Value.
To support its evaluation of best practices across multiple business performance categories, Frost & Sullivan employs a customised Decision Support Scorecard to allow research and consulting teams to objectively analyse performance according to key benchmarking criteria and to assign ratings on that basis. Respiri rated well above its identified competitors to secure the 2019 Best Practices Award.
Australian Financial Review
New app for asthma sufferers
About one in nine Australians – 2.7 million people – suffer from asthma, according to the Australian Institute of Health and Welfare. At least 421 people died from the disease in 2015 and the mortality rate is stubbornly hard to shift.
Medical technology innovator Respiri aims to change this with a new connected device, dubbed wheezo®, which records breath sounds to detect and measure ‘‘wheeze rate’’ – the extent of the coarse whistling sound produced when the airways are narrowed and inflamed.
